Stamford Pharmaceuticals Inc has relocated its head office to Texas

Stamford Pharmaceuticals, a clinical-stage onco-dermatology company, announced today that it has relocated its head office to Houston, Texas. Stamford Pharmaceuticals is currently undertaking a Phase 2a clinical trial, evaluating its lead agent, SP-002, as treatment for patients who present with multiple basal cell carcinomas. It is anticipated that the study will be completed in the second half of 2021.

“Stamford’s relocation from Connecticut marks a new growth phase in the company, which has plans to embark on its Phase 3 program in 2022,” said Dr Clement Leong, PhD, Chief Executive Officer of Stamford.

Press Release: Stamford Pharmaceuticals Inc has relocated its head office to Texas